6. It seems to me that the limitations of the study aren't adequately addressed. Sample size and lacking covariates come to mind. Introduction: 7. It is my understanding that the 5' untranslated end of TMPRSS2 is binds to the 3' end of ERG. 8. I don't consider TMPRSS2:ERG to be a genetic mutation so much as an alteration or aberration. 9. Is the prognostic value of TMPRSS2:ERG really still under debate? Perhaps in certain patient / treatment populations, but I think it has largely been established that the fusion isn't associated with worse outcomes (at least in those treated with radical prostatectomy Results: 15. The Methods indicate that an H-score of 0-50 resulted in an ERG-negative classification, but Figure 1 shows an ERG-positive individual with an H-score seemingly <50. 16. The authors might consider a trend test for some of the variables in Table 1 . 17. Figure 2 and its associated description in the manuscript strike me as somewhat beside the point of the study. So too with the description of the Table 2 results. 18. Log-rank evaluations don't account for the covariates that are likely to be important in the associations of interest.
Discussion:
19. The first paragraph of the Discussion should summarize the important findings of the study. 20. Again, I don't know that the term "mutation" is appropriate. 21. Perhaps more importantly than the high prevalence of ERG expression in all grades of disease, the largest of studies haven't shown an association between ERG expression and disease outcomes. Regardless, rather than focus on the (rather settled) debate about the association between ERG expression and outcomes overall, the authors should speak to their hypothesis that ERG expression could be associated with outcomes in their particular patient population. 22. The authors should be careful to avoid using the term "effect". They've only evaluated associations. 23. The first paragraph of the Limitations indicates that the patient population wasn't as described in the Methods. This point should be surfaced earlier. In addition, the authors should run sensitivity analyses in the patient population that truly received only ADT.
24. The authors need to discuss the limitations of their sample size. They could even consider calculating the power they had to find a reasonable magnitude of association. 25. The authors should discuss potentially important covariates for which they did not have data. Stage at diagnosis, for example, has been shown to be associated with ERG status and with prostate cancer outcomes.
Conclusion:
26. The value of the future study described is unclear. 27. Given their limited sample size, the authors should soften their conclusions.
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GENERAL COMMENTS
The authors contribute novel information in this study, in which they examine whether there is prognostic value of ERG in predicting prostate cancer (PCa) progression or death in a cohort of men who underwent primary ADT as monotherapy for treatment of high risk PCa (metastatic and non-metastatic). A key strength is use of a national registry to ascertain vital status. The paper is well written and the discussion section offers meaningful insight into how these data contribute uniquely to the field, while clearly recognizing the study's limitations. 
